脂质体布比卡因关节周围浸润在全膝关节置换术后24小时外的镇痛效果不优于普通布比卡因:系统综述与Meta分析
两组在累积口服吗啡当量消耗和静息痛评分曲线下面积方面均未检测到差异,平均差分别为0.54 mg(95%CI -5.09至6.18)和0.08 cm/小时(95%CI -0.19至0.35),证据质量高。二次结局分析未发现脂质体布比卡因在术后第2或第3天具有额外镇痛、功能或安全性优势。
要点
- 脂质体布比卡因与普通布比卡因关节周围浸润在全膝关节置换术后第2天镇痛效果无差异。
- 术后第3天亦未发现脂质体布比卡因在镇痛、功能恢复或安全性方面的额外优势。
- 高质量证据不支持在全膝关节置换术中使用脂质体布比卡因关节周围浸润。
核心结论
- 脂质体布比卡因与普通布比卡因关节周围浸润在全膝关节置换术后延长镇痛 outcomes 方面无差异,高质量证据不支持使用脂质体布比卡因。
主要发现
- 术后第2天累积口服吗啡当量消耗平均差为0.54 mg(95%CI -5.09至6.18),静息痛评分曲线下面积平均差为0.08 cm/小时(95%CI -0.19至0.35),均未检测到差异(高质量证据)。
- 二次结局分析未发现脂质体布比卡因在术后第2天或第3天具有额外镇痛、功能或安全性优势。
临床怎么用
- 基于高质量证据,全膝关节置换术关节周围浸润镇痛不应常规优先选择脂质体布比卡因而非普通布比卡因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Periarticular local infiltration analgesia (LIA) is integral to multimodal analgesia following total knee arthroplasty (TKA); however, the duration of analgesia using traditional long-acting local anesthetics is often insufficient. LIA with slow-release liposomal bupivacaine may provide extended analgesia, but evidence of efficacy beyond the first 24 hours is conflicting. This meta-analysis compares the effects of periarticular liposomal and plain bupivacaine LIA on day 2 analgesic outcomes post-TKA. Trials comparing liposomal and plain bupivacaine LIA for TKA were sought. The two coprimary outcomes were (1) cumulative oral morphine equivalent consumption and (2) difference in area under the curve (AUC) of pooled rest pain scores on day 2 (24-48 hours) post-TKA. We also evaluated pain and analgesic consumption on day 3 (48-72 hours), functional recovery, length of hospital stay, patient satisfaction; and opioid-related side effects. Data were pooled using random-effects modeling. Seventeen trials (1836 patients) were analyzed. Comparing liposomal versus plain bupivacaine LIA for TKA failed to detect differences in morphine consumption and pain AUC on day 2 postoperatively, with mean differences of 0.54 mg (95% CI -5.09 to 6.18) and 0.08 cm/hour (95% CI -0.19 to 0.35), respectively (high-quality evidence). Secondary outcome analysis did not uncover any additional analgesic, functional or safety advantages to liposomal bupivacaine on postoperative day 2 or 3. Results indicate that liposomal and plain bupivacaine LIAs are not different for extended postoperative analgesic outcomes, including pain control, opioid consumption, as well as functional and safety outcomes on days 2 and 3 post-TKA. High-quality evidence does not support using liposomal bupivacaine LIA for TKA.
引用
- Hussain N, Brull R, Sheehy BT, et al. The mornings after-periarticular liposomal bupivacaine infiltration does not improve analgesic outcomes beyond 24 hours following total knee arthroplasty: a systematic review and meta-analysis. Reg Anesth Pain Med. 2020. PMID: 33106282. doi:10.1136/rapm-2020-101995
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。